The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AEMD | -85.84% | -99.6% | -66.8% | -100% |
| S&P | +18.54% | +92.9% | +14.04% | +422% |
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.15M | -80.0% |
| Market Cap | $3.12M | 137.8% |
| Market Cap / Employee | $0.35M | 0.0% |
| Employees | 9 | -35.7% |
| Net Income | -$1.76M | 31.5% |
| EBITDA | -$1.64M | 35.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.77M | -58.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.26M | -55.6% |
| Short Term Debt | $0.43M | 45.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -150.45% | -66.0% |
| Return On Invested Capital | -130.60% | -35.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.71M | 1.9% |
| Operating Free Cash Flow | -$1.71M | 1.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.08 | 2.78 | 1.12 | 0.91 | 300.57% |
| Price to Sales | 9.60 | - | |||
| Price to Tangible Book Value | 59.69 | 159.61 | 92.44 | 4.70 | -74.16% |
| Enterprise Value to EBITDA | -0.16 | -4.57 | -0.56 | 0.36 | -79.74% |
| Return on Equity | -138.0% | -160.0% | -245.9% | -207.3% | 96.71% |
| Total Debt | $0.80M | $0.72M | $0.83M | $0.69M | -21.08% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
